Treatment of murine lupus with CTLA4Ig.

The interaction of B7-related molecules on antigen-presenting cells with CD28 or CTLA-4 antigens on T cells provides a second signal for T cell activation. Selection inhibition of the B7-CD28 or B7-CTLA-4 interactions produces antigen-specific T cell unresponsiveness in vitro and suppresses immune function in vivo. To determine whether selective inhibition of the B7-CD28 or B7-CTLA-4 interactions could suppress spontaneous autoimmune disease, a B7-binding protein was generated by genetic fusion of the extracellular domain of murine CTLA-4 to the Fc portion of a mouse immunoglobulin G2a monoclonal antibody (muCTLA4Ig). In lupus-prone NZB/NZW filial generation (F1) mice, treatment with muCTLA4Ig blocked autoantibody production and prolonged life, even when treatment was delayed until the most advanced stage of clinical illness. These findings suggest a possible role for human CTLA4Ig in the treatment of autoimmune diseases in humans.

[1]  Bucy Rp,et al.  Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. , 1994, Arthritis and rheumatism.

[2]  P. Lane,et al.  B cell function in mice transgenic for mCTLA4-H gamma 1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells , 1994, The Journal of experimental medicine.

[3]  B. Hausmann,et al.  Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo , 1994, The Journal of experimental medicine.

[4]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[5]  P. Linsley,et al.  Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. , 1993, Science.

[6]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[7]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[8]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Miller,et al.  The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. , 1992, Journal of immunology.

[10]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[11]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[12]  H. P. Fell,et al.  Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. , 1992, The Journal of biological chemistry.

[13]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[14]  A. Steinberg,et al.  NIH conference. Systemic lupus erythematosus. , 1991, Annals of internal medicine.

[15]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[16]  J. Gribben,et al.  B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[18]  P. Rabinovitch,et al.  CD28 ligation in T-cell activation: evidence for two signal transduction pathways. , 1990, Blood.

[19]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[20]  W. Seaman,et al.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4 , 1985, The Journal of experimental medicine.

[21]  S. Swain,et al.  Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. , 1984, Journal of immunology.

[22]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[23]  A. Weiss,et al.  The role of the T3/antigen receptor complex in T-cell activation. , 1986, Annual review of immunology.